The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.
more
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
Nature Reviews Microbiology Vol. 17 (2019)pp.51-62
Antimicrobial susceptibility testing (AST) technologies help to accelerate the
initiation of targeted antimicrobial therapy for patients with infections and could potentially
extend the lifespan of current narrow- spectrum antimicrobials. Althoug...h conceptually new and
rapid AST technologies have been described, including new phenotyping methods, digital
imaging and genomic approaches, there is no single major, or broadly accepted, technological
breakthrough that leads the field of rapid AST platform development
more
Standard Treatment Guidelines
HIV infection, due to the immunosuppressant that leads, nowadays constitutes an aggravating factor of endemic tuberculosis. Tuberculosis remains a huge burden to human health, even in the early 21st century. The situation is deteriorating in many countries, particularly because of the synergy with t...he HIV epidemic and the emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR) tuberculosis. The urgent development of new tools that can improve the diagnosis, prevention and/or treatment of tuberculosis and other major mycobacterium diseases depends largely on the progress of basic and applied research. Faced with this situation, there is an urgent need for effective strategies and actions to permanently solve the problem of this endemic disease whose impact is too negative on people’s lives.
more
The global impact of COVID-19 has been profound, and the public health threat it represents is the most serious seen in a respiratory virus since the 1918 H1N1 influenza pandemic. Here we present the results of epidemiological modelling which has informed policymaking in the UK and other countries i...n recent weeks.
more
The National Department of Health and Department of Agriculture, Forestry and Fisheries have collectively engaged to determine the key interventions that will form the basis for this strategy taking into account the recommendations from the WHO and OIE.
The development and implementation of a Natio...nal Antimicrobial Resistance Strategy Framework that complements international efforts is a major step towards containment of the growing threat of antimicrobial resistance in human and animal health. Global partnerships need to be strengthened because the responsibility for reducing resistance is a shared one. This responsibility is not only limited to the health care sector, but calls for collaborative action in all sectors - human, animal and agriculture.
The National Antimicrobial Resistance Strategy Framework will affect South Africa’s response to this looming threat. We already have the tools and expertise to make a difference, now all we need is to work together toward a better future.
more
4ª edição
Nos próximos meses, a COVID Reference apresentará atualizações regulares e narrará os dados científicos o mais coerente possível.
Lignes directrices provisoires, 13 août 2020
L’OMS a établi cette brève note d’information pour répondre au besoin de recommandations sur la prestation sûre de soins à domicile aux patients présumés atteints de l’infection par le nouveau coronavirus (2019-nCoV) présentant des symptô...mes bénins, et sur les mesures de santé publique liées à la prise en charge des contacts asymptomatiques.
more
COVID-19 e oxigênio: Os dados da China sugerem que embora a maioria das pessoas com COVID-19 tenham doença leve (40%) ou moderada (40%), cerca de 15% apresentam doença grave que requer oxigenoterapia, e 5% ficam em estado crítico e precisam de tratamento em uma unidade de terapia intensiva. Alé...m disso, a maioria dos pacientes críticos com COVID-19 precisará de ventilação mecânica.2,3 Por esses motivos, as unidades de saúde que tratam da COVID-19 devem estar equipadas com oxímetros de pulso, sistemas de oxigênio em funcionamento, incluindo interfaces de administração de oxigênio de uso único. A oxigenoterapia é recomendada para todos os pacientes graves e críticos com COVID-19, em doses baixas, variando de 1-2 L/min em crianças e começando com 5 L/min em adultos com cânula nasal, fluxos moderados para o uso em máscara de Venturi (6-10 L/min); ou fluxos mais altos (10-15 L/min) com o uso de uma máscara com bolsa reservatório. Além disso, o oxigênio pode ser administrado em fluxos mais altos e em concentrações maiores, usando uma cânula nasal de alto fluxo (CNAF)
more
Настоящее руководство «Клиническое ведение случаев COVID-19» базируется на
вышеуказанных стратегических приоритетах и адресовано клиницистам, участвующим в
оказа...ии помощи пациентам с подозреваемой или подтвержденной инфекцией COVID-19.
Оно не предназначено для того, чтобы заменить индивидуальное клиническое суждение или
консультацию специалиста, но призвано помочь клиническим работникам в обеспечении
наиболее эффективного ведения случаев. Повышенное внимание в настоящем руководстве
уделяется вопросам, касающимся особых и уязвимых групп населения, таких как дети,
пожилые люди и беременные женщины.
Interim guidance on clinical management COVID-19
more
How to respond to Covid19 pandemic in West and Central Africa
Центр лечения тяжелых острых респираторных инфекцийПрактическое руководство по организации центра лечения ТОРИ ицентра проведения скрининга на ТОРИ на базе мед...цинских учреждений
more
There is no secret to our procedure: the daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19. Many papers discussed in the Top 10 will eventually make it into subsequent editions of COVID Reference.